Supply of a medicinal product used in the treatment of patients with sympathetic neuroblastoma with dinutuximab beta (B.110)

Summary

The tender concerns successive deliveries of a medicinal product used in the treatment of patients with sympathetic neuroblastoma under the reimbursed dinutuximab beta treatment programme B.110 (ICD-10 C47). Quantities and product assortment are defined in the price form. The contract runs until 30 June 2027, with no partial bids, options or framework agreement. Price is the only award criterion and accounts for 100% of the score. Offers must be submitted electronically in Polish by 10 September 2026 at 09:00 via the purchasing platform. No bid guarantee or performance security is required.